Lv2
138 积分 2022-05-11 加入
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis
1个月前
已完结
Interleukin‐17 is a potential player and treatment target in severe chronic spontaneous urticaria
1个月前
已完结
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial
2个月前
已完结
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
2个月前
已完结
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
2个月前
已完结
Innovation in Alopecia Areata
2个月前
已完结
Association Between Serum Total IgE Levels and Clinical Response to Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis
3个月前
已完结
New Biological Treatment Options in CSU
4个月前
已完结
Rituximab in Refractory Chronic Spontaneous Urticaria: An Encouraging Therapeutic Approach
4个月前
已完结
Nemolizumab: First Approval
4个月前
已完结
皖公网安备34019202002308
